Minaprine

Minaprine
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	N06AX07 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	2-2.5 hours
Identifiers
	IUPAC name 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine;
CAS Number	25905-77-5 ;
PubChem CID	4199;
ChemSpider	4054 ;
UNII	00U7GX0NLM;
KEGG	D05039 ;
ChEMBL	ChEMBL278819 ;
CompTox Dashboard (EPA)	DTXSID5048477 ;
ECHA InfoCard	100.043.012
Chemical and physical data
Formula	C17H22N4O
Molar mass	298.383 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3;
	(what is this?) (verify)

Minaprine (Brantur, Cantor) is an antidepressant that was used in France for the treatment of depression until it was withdrawn from the market in 1996 because it caused convulsions.^[1]

A study found that it acts as a reversible inhibitor of MAO-A (RIMA) in rats.^[2] In a study it has also been found to weakly inhibit acetylcholinesterase in rat brain (striatum) homogenates.^[3]

References

^ Fung, M.; Thornton, A.; Mybeck, K.; Wu, J. H.-h.; Hornbuckle, K.; Muniz, E. (1 January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317. doi:10.1177/009286150103500134.
^ Kan JP, Mouget-Goniot C, Worms P, Biziere K (1986). "Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat". Biochemical Pharmacology. 35 (6): 973–978. doi:10.1016/0006-2952(86)90085-7. PMID 3954800.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Contreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG (1999). "Aminopyridazines as acetylcholinesterase inhibitors". Journal of Medicinal Chemistry. 42 (4): 730–741. doi:10.1021/jm981101z. PMID 10052979.{{cite journal}}: CS1 maint: multiple names: authors list (link)

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[Fung-2001-1] Fung, M.; Thornton, A.; Mybeck, K.; Wu, J. H.-h.; Hornbuckle, K.; Muniz, E. (1 January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317. doi:10.1177/009286150103500134.

[2] Kan JP, Mouget-Goniot C, Worms P, Biziere K (1986). "Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat". Biochemical Pharmacology. 35 (6): 973–978. doi:10.1016/0006-2952(86)90085-7. PMID 3954800.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[3] Contreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG (1999). "Aminopyridazines as acetylcholinesterase inhibitors". Journal of Medicinal Chemistry. 42 (4): 730–741. doi:10.1021/jm981101z. PMID 10052979.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[1]

[2]

[3]

v t e Anxiolytics (N05B)
5-HT_1ARTooltip 5-HT1A receptor agonists	Buspirone Gepirone Tandospirone
GABA_ARTooltip GABAA receptor PAMsTooltip positive allosteric modulators	Benzodiazepines: Adinazolam Alprazolam Bromazepam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Diazepam^# Ethyl loflazepate Etizolam Fludiazepam Halazepam Ketazolam Lorazepam^# Medazepam Nordazepam Oxazepam Pinazepam Prazepam; Others: Alpidem^‡ Barbiturates (e.g., phenobarbital) Carbamates (e.g., meprobamate) Carisoprodol Chlormezanone^‡ Ethanol (alcohol) Etifoxine
Hypnotics	Zopiclone
Gabapentinoids (α₂δ VDCC blockers)	Gabapentin Gabapentin enacarbil Phenibut Pregabalin
Antidepressants	SSRIsTooltip Selective serotonin reuptake inhibitors (e.g., escitalopram) SNRIsTooltip Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine) SARIsTooltip Serotonin antagonist and reuptake inhibitors (e.g., trazodone) TCAsTooltip Tricyclic antidepressants (e.g., clomipramine^#) TeCAsTooltip Tetracyclic antidepressants (e.g., mirtazapine) MAOIsTooltip Monoamine oxidase inhibitors (e.g., phenelzine); Others: Agomelatine Bupropion Tianeptine Vilazodone Vortioxetine
Antipsychotics	Quetiapine Flupentixol
Sympatholytics (Antiadrenergics)	Alpha-1 blockers (e.g., prazosin) Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine) Beta blockers (e.g., propranolol)
Others	Benzoctamine Cycloserine Fabomotizole Hydroxyzine Lorpiprazole Mebicar Mepiprazole Nicotine Opipramol Oxaflozane^‡ Phenaglycodol Phenibut Picamilon Selank Tiagabine Tofisopam Validolum
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

See also

References